These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 19081402

  • 1. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
    Belonje AM, Westenbrink BD, Voors AA, von Haehling S, Ponikowski P, Anker SD, van Veldhuisen DJ, Dickstein K.
    Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
    Møller JE, Dahlström U, Gøtzsche O, Lahiri A, Skagen K, Andersen GS, Egstrup K, OPTIMAAL Study Group.
    Am Heart J; 2004 Mar; 147(3):494-501. PubMed ID: 14999200
    [Abstract] [Full Text] [Related]

  • 4. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients.
    Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, Gullestad L, Dickstein K, Aukrust P.
    J Am Coll Cardiol; 2005 Dec 06; 46(11):2018-21. PubMed ID: 16325035
    [Abstract] [Full Text] [Related]

  • 5. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
    Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K.
    J Card Fail; 2007 Dec 06; 13(10):843-9. PubMed ID: 18068618
    [Abstract] [Full Text] [Related]

  • 6. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
    Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP, ELITE II Investigators.
    Am Heart J; 2005 Jul 06; 150(1):123-31. PubMed ID: 16084158
    [Abstract] [Full Text] [Related]

  • 7. Soluble CD40 ligand in acute and chronic heart failure.
    Ueland T, Aukrust P, Yndestad A, Otterdal K, Frøland SS, Dickstein K, Kjekshus J, Gullestad L, Damås JK.
    Eur Heart J; 2005 Jun 06; 26(11):1101-7. PubMed ID: 15716285
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.
    van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ.
    J Am Coll Cardiol; 2004 Jul 07; 44(1):63-7. PubMed ID: 15234408
    [Abstract] [Full Text] [Related]

  • 9. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
    Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, OPTIMAAL investigators.
    Eur Heart J; 2005 Feb 07; 26(4):350-6. PubMed ID: 15618041
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 11. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Dickstein K, Kjekshus J, OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Am J Cardiol; 2001 Mar 15; 87(6):766-71, A7. PubMed ID: 11249900
    [Abstract] [Full Text] [Related]

  • 12. Early and chronic captopril or Losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats.
    Martínez LA, Villalobos-Molina R.
    Arch Med Res; 2003 Mar 15; 34(5):357-61. PubMed ID: 14602500
    [Abstract] [Full Text] [Related]

  • 13. Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy.
    Ozdemir M, Arslan U, Türkoğlu S, Balcioğlu S, Cengel A.
    J Card Fail; 2007 Dec 15; 13(10):812-7. PubMed ID: 18068613
    [Abstract] [Full Text] [Related]

  • 14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 15; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 15. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
    Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
    Lancet; 2002 Sep 07; 360(9335):752-60. PubMed ID: 12241832
    [Abstract] [Full Text] [Related]

  • 16. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Sep 07; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 17. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
    Dickstein K.
    Am Heart J; 2003 May 07; 145(5):754-7. PubMed ID: 12766730
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction.
    Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T.
    Am Heart J; 2006 Nov 07; 152(5):927.e1-6. PubMed ID: 17070161
    [Abstract] [Full Text] [Related]

  • 19. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
    Wang AY, Yu AW, Lam CW, Yu LM, Li PK, Goh J, Lui SF.
    Am J Kidney Dis; 2002 Mar 07; 39(3):600-8. PubMed ID: 11877580
    [Abstract] [Full Text] [Related]

  • 20. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.
    Anker SD, Voors A, Okonko D, Clark AL, James MK, von Haehling S, Kjekshus J, Ponikowski P, Dickstein K, OPTIMAAL Investigators.
    Eur Heart J; 2009 Jun 07; 30(11):1331-9. PubMed ID: 19383732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.